DMAC
DiaMedica Therapeutics Inc.
Next earnings Aug 10, 2026 (after close) · consensus $-0.20 EPS
Last earnings +4.3% on 2026-05-06
$6.55
▲ +6.50%$6.55▲ +81.44%
over 1Y
L $3.57EODHDH $9.39
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+6.5%
1W+11.2%
1M+7.4%
3M-3.5%
YTD-17.4%
1Y+81.4%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 11 analysts
Buy
Unprofitable (net margin -6553.2%).
DiaMedica Therapeutics Inc. shows $500K in FY2018 revenue, a -6553.2% net margin, and -58.4% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$13.6M | -$14.0M | -$21.3M | -$26.7M | -$34.4M |
| Net income | -$13.6M | -$13.7M | -$19.4M | -$24.4M | -$32.8M |
| Diluted EPS | -$0.65 | — | — | — | — |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$337M
EV / EBITDA—
EV / Sales674.6
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-9.3%
FCF yield-8.2%
Quality & risk
ROIC (est.)-48.4%
Free cash flow-$29.1M
Total debt—
Net cash$15.6M
Piotroski F-Score2/6
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+25.7%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRoutine disclosure cadence — no material red flags in recent filings.
Recent filings
all on EDGAR ↗4Period ending 2026-06-012026-06-03open ↗4Period ending 2026-06-012026-06-03open ↗4Period ending 2026-06-012026-06-03open ↗4Period ending 2026-06-012026-06-03open ↗4Period ending 2026-06-012026-06-03open ↗4Period ending 2026-06-012026-06-03open ↗4Period ending 2026-06-012026-06-03open ↗4Period ending 2026-06-012026-06-03open ↗4Period ending 2026-06-012026-06-03open ↗8-KPeriod ending 2026-05-202026-05-21open ↗10-QPeriod ending 2026-03-312026-05-06open ↗8-KPeriod ending 2026-05-062026-05-06open ↗
Frequently asked
- Is DiaMedica Therapeutics Inc. (DMAC) a buy?
- DMAC currently carries a Sell rating with 3/5 conviction, derived from its latest SEC filings. Unprofitable (net margin -6553.2%).
- What is DiaMedica Therapeutics Inc.'s quality score?
- DMAC scores 27.862745098039213/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001401040, latest 10-Q filed 2026-05-06) · EODHD · as of 6/23/2026, 12:43:38 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.